Description
Reg. No. G4083 (Act 36/1947)
Namibia Reg. No. V14/18.3.10/1259 [NS0]
NAFDAC Reg. No. A9-100511, A9-100512, A9-100513, A9-100514, A9-100515
INDICATIONS
For the treatment and prevention of tick, flea and mite infestations in dogs. Bravecto® kills adult, and juvenile ticks (larvae and nymphs). Bravecto® can be used as part of a treatment strategy for flea allergy dermatitis (FAD). For the treatment of Demodicosis caused by Demodex spp. and Sarcoptic mange mites. In a controlled trial, treatment with fluralaner resulted in the complete removal of Demodex spp. mites from treated dogs.
For the treatment of Otodectes spp. ear mite infestations.
The flea insecticidal efficacy of Bravecto® (fluralaner) significantly reduces the likelihood of Dipylidium caninum (tapeworm) transmission from fleas to susceptible dogs throughout the 84 days following a single treatment, by controlling fleas on dogs and lowering the flea burden in the dog’s immediate environment.
COMPOSITION
Contains fluralaner equivalent to 25 to 56 mg/kg body weight.
Each chewable tablet contains:
Extra-Large Dogs: 1 400 mg
Excipients: aspartame, disodium embonate monohydrate, glycerol, liver flavour, Macrogol 3350, magnesium stearate, maize starch, sodium lauryl sulphate, soyabean oil, sucrose.